Global

International Day Against Drug Abuse and Illicit Trafficking 2026

The International Day Against Drug Abuse and Illicit Trafficking is observed each year on June 26. Proclaimed by the United Nations General Assembly through resolution 42/112, this day calls attention to the global impact of drug abuse and trafficking. It urges governments, institutions, and civil society to take coordinated action to prevent drug-related harm and address the challenges associated with organized crime and public health.

More than 800 people from over 75 countries came together virtually on 3rd June 2025 for the eleventh edition of the RELX SDG Inspiration Day: "The Future of Philanthropy: Stepping up for the SDGs" The annual online event brings together together business, academia, NGOs and government to explore pressing issues and inspire action on the United Nations Sustainable Development Goals (SDGs). Explore highlights from the day including inspiring keynotes from Ban Ki-moon, 8th Secretary General of the United Nations, Sir Lenny Henry and Sarah, Duchess of York.

Elsevier,

Journal of Endometriosis and Uterine Disorders, 2025, 100124

This study examined racial/ethnic disparities in the surgical management of endometriosis using data from the National Survey of Family Growth (NSFG) 2017-2019 cycle.�

World map with SDG icons and people

Recognising our customer's efforts to advance the United Nations Sustainable Development Goals.

This chapter provides a comprehensive overview of Prader-Willi syndrome (PWS), emphasizing its genetic basis, clinical features, and the importance of early diagnosis and multidisciplinary care. It aligns with SDG 3 (Good Health and Well-being) by promoting precision medicine and interventions to improve health outcomes, and SDG 10 (Reduced Inequalities) by advocating equitable access to specialized care and innovative treatments for individuals with PWS.

The article discusses the need for and challenges of developing combination therapies for Alzheimer's disease, given the complex and multifactorial nature of the disease. As of 2024, there were 21 combination trials in the pipeline, primarily involving repurposed agents targeting processes like inflammation, senescence, and amyloid-tau interactions. Key challenges include distinguishing individual drug effects and managing the operational complexity of combination trials.f
The article discusses the critical role of the mitochondrial contact site and cristae organizing system (MICOS) complex in the pathogenesis of Alzheimer's disease (AD). It highlights how MICOS abnormalities, including subunit dysfunction and interactions with disease-associated proteins, to hallmark AD pathologies such as amyloid-β accumulation, neurofibrillary tangle formation, and neuronal apoptosis. The article suggests that targeting MICOS subunits with pharmacological interventions may provide novel therapeutic insights for AD treatment.
The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.
This study indicates neurofibrillary tangles(NFT) level detection in patients with extracranial carotid atherosclerotic disease (ECAD) could enable earlier identification of those at high risk for developing Alzheimer's and other dementias, sometimes decades before symptoms. As blood-based assays to quantify NFT's are more clinically available, this could guide more targeted prevention and early treatment strategies for patients.

Pages